Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Stopped early · Phase 1/Phase 2

Conditions studied: Multiple Myeloma, Plasma Cell Neoplasm

In brief

Patients with previously treated multiple myeloma and kidney dysfunction will be treated with lenalidomide and low-dose dexamethasone. Phase I will study the side effects and best dose of lenalidomide when given together with low-dose dexamethasone therapy. After the maximum safe and tolerated dose is found in Phase I, the study will proceed to Phase II. Phase II will study how well the the treatment works in patients with previously treated (relapsed or refractory) multiple myeloma and kidney dysfunction. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with dexamethasone may kill more cancer cells. Lenalidomide and dexamethasone may have different effects in patients who have changes in their kidney function.

Key facts

Study ID

NCT00790842

Run by

PrECOG, LLC.

People needed

63

Starts

2009-01-21

Expected to finish

2018-03-08

Last updated by the study team

2018-10-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with previously treated multiple myeloma.
• Measurable disease assessed by one of the following ≤21 days prior to registration:
• Serum monoclonal protein ≥1 g by protein electrophoresis
• Urine monoclonal protein >200 mg on 24 hour electrophoresis
• Serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa to lambda free light chain ratio
• Monoclonal bone marrow plasmacytosis ≥30% (evaluable disease)
• If both serum and urine m-components are present, both must be followed in order to evaluate response.
• All previous cancer therapy including chemotherapy, radiation, hormonal therapy and surgery, must be discontinued ≥2 weeks prior to registration.
• Age ≥18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Acceptable organ and marrow function ≤21 days prior to registration:
• Absolute neutrophil count (ANC) ≥1000/mm³
• Platelet count ≥75,000/mm³
• Total bilirubin ≤2 mg/dL
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 x upper limit of normal
• Renal impairment at baseline as measured by serum creatinine clearance (CrCl) ≤60 mL/min ≤21 days prior to registration.
• Females of Childbearing Potential (FCBP) must have a negative pregnancy test within 10-14 days and again within 24 hours of starting Cycle 1 and must use an effective double-method contraception for ≥28 days prior to, during, and for ≥28 days after completion of study therapy.
• Able to take required prophylactic anticoagulation.
• Able to understand and willingness to sign a written informed consent.
• Willing to provide blood samples for research purposes (Mayo Clinic sites only).
• If previously received lenalidomide, demonstration of clinical response of any duration or stable disease with progression-free interval of ≥6 months from start of that therapy.

You may not qualify if…

• Concurrent use of other anti-cancer agents or treatments. Growth factors and bisphosphonates are allowed as medically indicated. Steroids may be used with an equivalency of up to 20 mg of Prednisone per day as long as the dose has not been adjusted upwards in past 2 weeks prior to study registration.
• Uncontrolled intercurrent illness including, but not limited to, any of the following:
• Ongoing or active infection requiring IV antibiotics
• Symptomatic congestive heart failure
• Unstable angina pectoris
• Uncontrolled cardiac arrhythmia
• Psychiatric illness/social situation that would limit compliance with study requirements.
• Any of the following as this regimen may be harmful to a developing fetus or nursing child:
• Pregnant women
• Breast-feeding women
• Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception.
• HIV-positive patients on combination antiretroviral therapy.
• Known hypersensitivity to thalidomide or other immunomodulatory drugs.
• History of Stevens-Johnson syndrome characterized by a desquamating rash while taking thalidomide or similar drugs.
• Other active malignancy except for non melanoma skin cancer or in situ cervical or breast cancer.
• Concurrent radiation therapy, except for palliation of a single painful bone lesion or fracture.

Where it is running

• Mayo Clinic in Arizona — Scottsdale, Arizona, United States
• Emory University Winship Cancer — Atlanta, Georgia, United States
• University of IL at Chicago — Chicago, Illinois, United States
• McFarland Clinic — Ames, Iowa, United States
• Siouxland Hematology Oncology Associates — Sioux City, Iowa, United States
• Michigan Cancer Research Consortium and Oncology Research- St. Joseph Mercy Hospital - Ann Arbor — Ann Arbor, Michigan, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Metro MN CCOP — Saint Louis Park, Minnesota, United States
• Missouri Valley Cancer Consortium — Omaha, Nebraska, United States
• Kinston Medical Specialists — Kinston, North Carolina, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Reading Hospital and Medical Center — West Reading, Pennsylvania, United States
• WVU Mary Babb Randolph Cancer Center — Morgantown, West Virginia, United States
• Gundersen Lutheran — La Crosse, Wisconsin, United States
• Waukesha Memorial Hospital (ProHealth Care) — Waukesha, Wisconsin, United States
• Aurora Cancer Center — Wauwatosa, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.